CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenues:
Obstructive sleep apnea (OSA) - related	$ 300,098	$ 524,172
Total revenues	300,098	524,172
Costs and expenses:
Costs of revenues	145,254	261,170
Selling, general and administrative	2,092,806	1,745,094
Depreciation and amortization	609	599
Total costs and expenses	2,238,669	2,006,863
Operating loss	(1,938,571)	(1,482,691)
Other income (expense):
Interest expense	(1,428,671)	(1,436,974)
Legal settlement	112,172	215,848
Setttlement of prior accounting services		(240,000)
Extinguishment of loan due to shareholder		7,771,140
Tax penalty	(6,794)	(50)
Interest income	6,050
Other income		2,380
Total other income (expense)	(1,317,243)	6,312,344
Net income (loss)	$ (3,255,814)	$ 4,829,653
PER SHARE INFORMATION
Basic	$ (0.05)	$ 0.07
Weighted average number of common shares outstanding	69,161,656	65,362,240